Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Orphan Drug Designation for GW's cannabis seizure treatment

GW Pharmaceuticals advances its cannabis-based drug repertoire with FDA approval.
An orphan with wires attached to his brain.
Epilepsy is the leading cause of death in sufferers of TSC.

Biotech group GW Pharmaceuticals PLC (NASDAQ:GWPH LON:GWP) has been granted exclusive approval for its cannabis-based seizure treatment.

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the group’s cannabidiol (CBD) for the treatment of the rare genetic disorder, Tuberous Sclerosis Complex (TSC).

The drug is the third orphan indication that the group is targeting within it Epidiolec clinical development program. Earlier this month the group commenced phase III clinical trials for the CBD treatment as a therapy to treat seizures in combination with other TSC treatments.

A common symptom of TSC is epilepsy, which occurs in around 80-90% of sufferers and is the leading cause of morbidity and mortality.

The Epidiolec  program includes a further four phase III pivotal trials in Dravet syndrome and Lennox-Gastaut syndrome, both rare and fatal forms of childhood-onset epilepsy.

The FDA Orphan Drug Designation entitles GW Pharmaceuticals to a seven-year exclusive market period.

Shares were up almost 2% on AIM this morning to 515p per share. On NASDAQ, GW shares last traded at $86.23 up by around 4%.



Register here to be notified of future GWP Company articles
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

picture of drug research
June 05 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Pollen2.jpg
January 19 2017
Turnover was £40.4mln in the six months to December
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use